WO2007123722A2 - Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse - Google Patents

Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse Download PDF

Info

Publication number
WO2007123722A2
WO2007123722A2 PCT/US2007/007965 US2007007965W WO2007123722A2 WO 2007123722 A2 WO2007123722 A2 WO 2007123722A2 US 2007007965 W US2007007965 W US 2007007965W WO 2007123722 A2 WO2007123722 A2 WO 2007123722A2
Authority
WO
WIPO (PCT)
Prior art keywords
sorafenib
mmp
subject
amount
cell
Prior art date
Application number
PCT/US2007/007965
Other languages
English (en)
Other versions
WO2007123722A3 (fr
Inventor
Scott Wilhelm
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Priority to JP2009503038A priority Critical patent/JP2009532029A/ja
Priority to CA002648106A priority patent/CA2648106A1/fr
Priority to EP07754481A priority patent/EP2002264A2/fr
Publication of WO2007123722A2 publication Critical patent/WO2007123722A2/fr
Publication of WO2007123722A3 publication Critical patent/WO2007123722A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne également les biomarqueurs et l'utilisation de biomarqueurs dans le cadre de la prévision et du pronostic d'un cancer, ainsi que l'utilisation de biomarqueurs en vue de surveiller l'efficacité d'un traitement anticancéreux.
PCT/US2007/007965 2006-03-31 2007-03-30 Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse WO2007123722A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009503038A JP2009532029A (ja) 2006-03-31 2007-03-30 癌の予報および予後方法および癌治療のモニタリング
CA002648106A CA2648106A1 (fr) 2006-03-31 2007-03-30 Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
EP07754481A EP2002264A2 (fr) 2006-03-31 2007-03-30 Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78769306P 2006-03-31 2006-03-31
US60/787,693 2006-03-31
US90168207P 2007-02-16 2007-02-16
US60/901,682 2007-02-16

Publications (2)

Publication Number Publication Date
WO2007123722A2 true WO2007123722A2 (fr) 2007-11-01
WO2007123722A3 WO2007123722A3 (fr) 2008-05-08

Family

ID=38430446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007965 WO2007123722A2 (fr) 2006-03-31 2007-03-30 Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse

Country Status (4)

Country Link
EP (1) EP2002264A2 (fr)
JP (1) JP2009532029A (fr)
CA (1) CA2648106A1 (fr)
WO (1) WO2007123722A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061800A2 (fr) * 2007-11-09 2009-05-14 Genentech, Inc. Procédés et compositions pour une utilisation de diagnostic chez des patients atteints de cancer
WO2010022227A1 (fr) * 2008-08-20 2010-02-25 Schering Corporation Procédés pour surveiller une thérapie il-10
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
JP2011528014A (ja) * 2008-07-14 2011-11-10 ジーイー・ヘルスケア・リミテッド 治療のモニタリング
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2012506560A (ja) * 2008-10-21 2012-03-15 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
US20210029131A1 (en) * 2016-12-20 2021-01-28 Google Llc Conditional provision of access by interactive assistant modules
US11822695B2 (en) 2018-08-07 2023-11-21 Google Llc Assembling and evaluating automated assistant responses for privacy concerns

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105074467B (zh) * 2013-04-25 2018-06-15 株式会社Cbs生物科学 提高分子靶向治疗肝细胞癌的敏感性的分析方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015947A2 (fr) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methodes et trousses pour la prediction du succes therapeutique, de la survie sans recidive et globale dans des therapies du cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015947A2 (fr) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methodes et trousses pour la prediction du succes therapeutique, de la survie sans recidive et globale dans des therapies du cancer

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CARLOMAGNO FRANCESCA ET AL: "BAY 43-9006 inhibition of oncogenic RET mutants." JOURNAL OF THE NATIONAL CANCER INSTITUTE 1 MAR 2006, vol. 98, no. 5, 1 March 2006 (2006-03-01), pages 326-334, XP002448750 ISSN: 1460-2105 *
CHANG YONG S ET AL: "Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models." CANCER CHEMOTHERAPY AND PHARMACOLOGY APR 2007, vol. 59, no. 5, April 2007 (2007-04), pages 561-574, XP002464783 ISSN: 0344-5704 *
CLARK JEFFREY W ET AL: "Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 AUG 2005, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5472-5480, XP002448749 ISSN: 1078-0432 *
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 October 2004 (2004-10-01), WILHELM SCOTT M ET AL: "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis." XP002448752 Database accession no. NLM15466206 & CANCER RESEARCH 1 OCT 2004, vol. 64, no. 19, 1 October 2004 (2004-10-01), pages 7099-7109, ISSN: 0008-5472 *
HEIM MARTINA ET AL: "The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines." ANTI-CANCER DRUGS FEB 2005, vol. 16, no. 2, February 2005 (2005-02), pages 129-136, XP009088785 ISSN: 0959-4973 *
KUEFER R ET AL: "Translational research in renal cell cancer; Illustrated by the example of the vascular endothelial growth factor pathway" DER UROLOGE, AUSGABE A ; ZEITSCHRIFT FÜR KLINISCHE UND PRAKTISCHE UROLOGIE ORGAN DER DEUTSCHEN GESELLSCHAFT FÜR UROLOGIE, SPRINGER-VERLAG, BE, vol. 45, no. 3, 1 March 2006 (2006-03-01), pages 328-335, XP019321736 ISSN: 1433-0563 *
LUO ET AL: "Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model" INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 63, no. 2, 1 October 2005 (2005-10-01), pages 553-564, XP005077610 ISSN: 0360-3016 *
SHI Q ET AL: "Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NOV 1999, vol. 5, no. 11, November 1999 (1999-11), pages 3711-3721, XP002464785 ISSN: 1078-0432 *
TAMM M ET AL: "Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells." AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY OCT 1998, vol. 19, no. 4, October 1998 (1998-10), pages 653-661, XP002464787 ISSN: 1044-1549 *
WOUTERS BRADLY G ET AL: "Targeting hypoxia tolerance in cancer." DRUG RESISTANCE UPDATES : REVIEWS AND COMMENTARIES IN ANTIMICROBIAL AND ANTICANCER CHEMOTHERAPY FEB 2004, vol. 7, no. 1, February 2004 (2004-02), pages 25-40, XP002464784 ISSN: 1368-7646 *
XU L ET AL: "Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells." CANCER RESEARCH 15 NOV 1999, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5822-5829, XP002464786 ISSN: 0008-5472 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841330B2 (en) 1999-01-13 2014-09-23 Bayer Healthcare Llc Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8242147B2 (en) 2002-02-11 2012-08-14 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US8618141B2 (en) 2002-02-11 2013-12-31 Bayer Healthcare Llc Aryl ureas with angiogenesis inhibiting activity
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2009061800A3 (fr) * 2007-11-09 2009-07-16 Genentech Inc Procédés et compositions pour une utilisation de diagnostic chez des patients atteints de cancer
WO2009061800A2 (fr) * 2007-11-09 2009-05-14 Genentech, Inc. Procédés et compositions pour une utilisation de diagnostic chez des patients atteints de cancer
JP2011528014A (ja) * 2008-07-14 2011-11-10 ジーイー・ヘルスケア・リミテッド 治療のモニタリング
WO2010022227A1 (fr) * 2008-08-20 2010-02-25 Schering Corporation Procédés pour surveiller une thérapie il-10
JP2012506560A (ja) * 2008-10-21 2012-03-15 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
US20210029131A1 (en) * 2016-12-20 2021-01-28 Google Llc Conditional provision of access by interactive assistant modules
US11822695B2 (en) 2018-08-07 2023-11-21 Google Llc Assembling and evaluating automated assistant responses for privacy concerns
US11966494B2 (en) 2018-08-07 2024-04-23 Google Llc Threshold-based assembly of remote automated assistant responses

Also Published As

Publication number Publication date
CA2648106A1 (fr) 2007-11-01
EP2002264A2 (fr) 2008-12-17
JP2009532029A (ja) 2009-09-10
WO2007123722A3 (fr) 2008-05-08

Similar Documents

Publication Publication Date Title
US8329408B2 (en) Methods for prognosis and monitoring cancer therapy
US20070178494A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP2002264A2 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
US20040146921A1 (en) Expression profiles for colon cancer and methods of use
EP1945819B1 (fr) Profils d'expression genique et procedes d'utilisation
US20070065827A1 (en) Gene expression profiles and methods of use
US20040191819A1 (en) Expression profiles for breast cancer and methods of use
WO2005032495A2 (fr) Profils d'expression genique et leurs methodes d'utilisation
US20070134670A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2011146725A1 (fr) Biomarqueurs pour un inhibiteur à multiples kinases
US20040121375A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2006032009A2 (fr) Procedes de prevision et de pronostic du cancer et de suivi de la therapie du cancer
WO2005067650A2 (fr) Profils d'expression genetique et methodes d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754481

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009503038

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2648106

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007754481

Country of ref document: EP